{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:57:08Z","timestamp":1791453428981,"version":"4.3.3"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.revmed.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T12:34:50Z","timestamp":1766147690000},"page":"84-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u00c9volution de la nomenclature des maladies h\u00e9patiques st\u00e9atosiques\u00a0: vers un changement de paradigme"],"prefix":"10.1016","volume":"47","author":[{"given":"Philippe","family":"Halfon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.revmed.2025.12.003_bib0205","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1053\/j.gastro.2020.04.048","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease and advanced fibrosis in general population: the French Nationwide NASH-CO Study","volume":"159","author":"Nabi","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.revmed.2025.12.003_bib0210","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.revmed.2025.12.003_bib0215","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2025.12.003_bib0220","doi-asserted-by":"crossref","first-page":"155642","DOI":"10.1016\/j.metabol.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"146","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.revmed.2025.12.003_bib0225","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u00a0\u2013\u00a0Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.revmed.2025.12.003_bib0230","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.revmed.2025.12.003_bib0235","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jhep.2023.08.018","article-title":"Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study","volume":"79","author":"Ebrahimi","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.revmed.2025.12.003_bib0240","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B","volume":"71","author":"Choi","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.revmed.2025.12.003_bib0245","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2337\/dc23-1937","article-title":"Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes","volume":"47","author":"Shang","year":"2024","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.revmed.2025.12.003_bib0250","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.revmed.2025.12.003_bib0255","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/j.jhep.2023.10.008","article-title":"Reply to: \u201cFrom NAFLD to MASLD: promise and pitfalls of a new definition\u201d: EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease","volume":"81","author":"Rinella","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.revmed.2025.12.003_bib0260","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.revmed.2025.12.003_bib0265","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2022.12.025","article-title":"Rational combination therapy for NASH: insights from clinical trials and error","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.revmed.2025.12.003_bib0270","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.revmed.2025.12.003_bib0275","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study","volume":"9","author":"Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.revmed.2025.12.003_bib0280","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/genes15040455","article-title":"Relevance of PNPLA3, TM6SF2, HSD17B13, and GCKR variants to MASLD severity in an Egyptian population","volume":"15","author":"Elmansoury","year":"2024","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.revmed.2025.12.003_bib0285","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12944-020-01207-9","article-title":"Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease","volume":"19","author":"Wu","year":"2020","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10.1016\/j.revmed.2025.12.003_bib0290","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jcmgh.2021.11.007","article-title":"TM6SF2\/PNPLA3\/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models","volume":"13","author":"Longo","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.revmed.2025.12.003_bib0295","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: from new variants to the clinic","volume":"72","author":"Tr\u00e9po","year":"2020","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.revmed.2025.12.003_bib0300","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.revmed.2025.12.003_bib0305","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.revmed.2025.12.003_bib0310","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.revmed.2025.12.003_bib0315","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.revmed.2025.12.003_bib0320","doi-asserted-by":"crossref","first-page":"e1001324","DOI":"10.1371\/journal.pgen.1001324","article-title":"Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits","volume":"7","author":"Speliotes","year":"2011","journal-title":"PLoS Genet"},{"issue":"12","key":"10.1016\/j.revmed.2025.12.003_bib0325","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.revmed.2025.12.003_bib0330","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1056\/NEJMoa0907295","article-title":"Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease","volume":"362","author":"Petersen","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.revmed.2025.12.003_bib0335","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2025.12.003_bib0340","doi-asserted-by":"crossref","first-page":"737759","DOI":"10.3389\/fmed.2021.737759","article-title":"Genetic polymorphisms and clinical features in diabetic patients with fatty liver: results from a single-center experience in Southern Italy","volume":"8","author":"Villani","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.revmed.2025.12.003_bib0345","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00441-011-1246-y","article-title":"TGF-\u03b2 in progression of liver disease","volume":"347","author":"Dooley","year":"2012","journal-title":"Cell Tissue Res"},{"issue":"11","key":"10.1016\/j.revmed.2025.12.003_bib0350","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3748\/wjg.v16.i11.1321","article-title":"Alcoholic liver disease and the gut-liver axis","volume":"16","author":"Szabo","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"10319","key":"10.1016\/j.revmed.2025.12.003_bib0355","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.revmed.2025.12.003_bib0360","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of Diabetes (EASD)","year":"2016","journal-title":"J Hepatol"},{"issue":"10019","key":"10.1016\/j.revmed.2025.12.003_bib0365","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.revmed.2025.12.003_bib0370","first-page":"e6","article-title":"Semaglutide or placebo for nonalcoholic steatohepatitis. Reply","volume":"385","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.revmed.2025.12.003_bib0375","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.revmed.2025.12.003_bib0380","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.revmed.2025.12.003_bib0385","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3390\/biomedicines12102328","article-title":"Comparative analysis of resmetirom vs. FGF21 analogs vs. GLP-1 agonists in MASLD and MASH: network meta-analysis of clinical trials","volume":"12","author":"Ayesh","year":"2024","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.revmed.2025.12.003_bib0390","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","article-title":"FGF21 reverses MASH through coordinated actions on the CNS and liver","volume":"37","author":"Rose","year":"2025","journal-title":"Cell Metab"},{"issue":"17","key":"10.1016\/j.revmed.2025.12.003_bib0395","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2025.12.003_bib0200","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat Commun"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325013335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325013335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:41:20Z","timestamp":1771429280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866325013335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0248866325013335"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2025.12.003","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9volution de la nomenclature des maladies h\u00e9patiques st\u00e9atosiques\u00a0: vers un changement de paradigme","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}